Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers

KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review

(2016) Lei Zhou et al.   MEDICAL ONCOLOGY

A combinatorial strategy for treating KRAS-mutant lung cancer

(2016) Eusebio Manchado et al.   NATURE

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

(2016) P. Lito et al.   SCIENCE

Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing

(2016) Nana Zhang et al.   PLoS One

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

(2015) P A Jänne et al.   BRITISH JOURNAL OF CANCER

Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer

(2015) P. Pettazzoni et al.   CANCER RESEARCH

Identification of a Novel Pathogenic Germline KDR Variant in Melanoma

(2015) I. P. Silva et al.   CLINICAL CANCER RESEARCH

KRAS-G12C Mutation is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma

(2015) Ernest Nadal et al.   Journal of Thoracic Oncology

Whole genomes redefine the mutational landscape of pancreatic cancer

(2015) Nicola Waddell et al.   NATURE

Molecular landscape of pancreatic cancer: implications for current clinical trials

(2015) Gregory M. Heestand et al.   Oncotarget

Inhibition of the Growth of Patient-Derived Pancreatic Cancer Xenografts with the MEK Inhibitor Trametinib Is Augmented by Combined Treatment with the Epidermal Growth Factor Receptor/HER2 Inhibitor Lapatinib

(2015) Dustin M. Walters et al.   NEOPLASIA

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

(2014) L. Rahib et al.   CANCER RESEARCH

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

(2014) P. L. Bedard et al.   CLINICAL CANCER RESEARCH

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

(2014) Jeffrey R. Infante et al.   EUROPEAN JOURNAL OF CANCER

COSMIC: exploring the world's knowledge of somatic mutations in human cancer

(2014) Simon A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor

(2014) Melissa Dumble et al.   PLoS One

KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer

(2013) D. P. Modest et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma

(2013) O. K. Mirzoeva et al.   MOLECULAR CANCER THERAPEUTICS

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

(2012) Nathan T. Ihle et al.   JNCI-Journal of the National Cancer Institute

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

(2012) Eric A. Collisson et al.   Cancer Discovery

Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer

(2011) Dylan M. Glubb et al.   CLINICAL CANCER RESEARCH

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

(2011) György Bodoky et al.   INVESTIGATIONAL NEW DRUGS

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Ligand-dependent Notch Signaling Is Involved in Tumor Initiation and Tumor Maintenance in Pancreatic Cancer

(2009) M. E. Mullendore et al.   CLINICAL CANCER RESEARCH

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE